Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05399433

Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis

Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse. This activation requires their migration from the cutaneous sensitisation site to the lymph nodes. This migration requires an important intracellular metabolic activity, with a strong involvmenet of glucdic metabolism. This activity is linked with the systemic activity. This study aims to compare the migration and the phenotypic and metabolic caracteristics of blood and skin DCs in patients with or without psoriasis and with or without type 2 diabetes,

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Nice

Nice, Alpes-maritimes, 06001, France

Location status: Recruiting

Location contact

Passeron Thierry

CONTACT

[email protected]

+3349204688

Passeron Thierry, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes
  • hospitalized in the Dermatology department of the CHU of Nice for moderate to severe psoriasis (defined by a PASI > or = 10)
  • covered by a social security scheme after obtaining a free
  • Clinical diagnosis of plaque psoriasis by a dermatologist with or without type 2 diabetes (defined by glycated hemoglobin >7%)
  • For the control group: without psoriasis or other inflammatory dermatosis aged in the presence or not of type 2 diabetes (glycated hemoglobin >7%).
  • free and informed consent

Exclusion criteria

  • Minor or incapable or unwilling to consent freely or in an informed manner Pregnant or nursing woman.
  • Patient in a period of exclusion from other biomedical research
  • Patient with generalized chronic inflammatory disease or other inflammatory dermatosis
  • Patients on general corticosteroid, immunomodulator or immunosuppressant therapy in the month prior to local inclusion or treatment with corticosteroid therapy in the 15 days prior to inclusion, on anti- treatmentIL-23 or anti IL12/23 for less than 3 months or under anti-IL-17 or anti-TNF treatment for less than 1 month.
  • Contraindication to cutaneous biospsis (known hemostasis disorder, taking anticoagulants, allergy to xylocaine, history of cheloid scars, congenital immune deficiency)

Treatment and study plan

Biopsy and venous blood

Other

A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.

Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis

Primary outcomes

  1. Percentage of dentridic cells producers of IL-23

    Time frame: at baseline

    Alterations in the percentage of dentridic cells that have migrated with the metabolic status of patients

Secondary outcomes

  1. Percentage of subpopulations dentridic cells producers

    Time frame: At baseline

    Study of the percentage of the various cDC subpopulations according to the metabolic status of the patients.

Study contacts

Contact information is provided by the study sponsor or research team.

PASSERON Thierry, PhD

CONTACT

[email protected]

+33492036488

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Rôle du métabolisme du Glucose Dans la Migration Des Cellules Dendritiques cutanées Dans le Psoriasis : étude Pilote Translationnelle

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jun 1, 2022
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.